TELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TELA Bio, Inc. (NASDAQ: TELA), a leader in soft-tissue reconstruction solutions, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's management team is set to present on August 14th, 2024, at 10:30 am ET. This event provides an opportunity for TELA Bio to showcase its innovative medical technology and growth strategies to investors and industry professionals.
Interested parties can access both the live presentation and archived webcast through TELA Bio's investor relations website at ir.telabio.com. This participation underscores TELA Bio's commitment to engaging with the investment community and highlights its position in the rapidly evolving medical technology sector.
Details
News Market Reaction – TELA
The recorded move for TELA in the trading session of this news was +2.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 44th Annual Growth Conference.
TELA’s management is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference at 10:30 am ET on August 14th, 2024. Interested parties can access the live and archived webcast at ir.telabio.com.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Investor Contact
Greg Chodaczek
347-620-7010
ir@telabio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.